RxDoctor Payments DataLook up a doctor →

Kenneth Chan, DO

Neurology · Jonesboro, ARNPI 1720042138

Payments from drug & device makers

$20,376in general payments, 2019–2025

Across 581 payments — averaging $35.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$10K
  • AbbVie$2K
  • Novartis$1K
  • Biogen$1K
  • AstraZeneca$620
  • UCB, Inc.$542
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$1501%
  • Food & beverage$10,01298%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,376 in reported general payments places this provider in the 75th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$434,741
Medicare patients
1,144
Services billed
21,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlatopaGlatiramer Acetate19$49,338
XcopriCenobamate26$45,420
UbrelvyUbrogepant29$31,125
NayzilamMidazolam36$23,568
Nurtec OdtRimegepant Sulfate16$22,508
BriviactBrivaracetam12$17,340
QuliptaAtogepant13$13,997
Galantamine ErGalantamine Hbr91$5,258
Primidone212$3,157
Oxcarbazepine11$3,127
Carbidopa-LevodopaCarbidopa/Levodopa137$2,783
Lamotrigine184$2,676
Memantine Hcl198$2,463
Depakote SprinkleDivalproex Sodium12$2,260
Pyridostigmine Bromide40$2,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$18$45,42026 claims
AbbVieUbrelvy, Qulipta$2,051$45,12242 claims
UCB, Inc.Nayzilam, Briviact$542$40,90848 claims
PfizerNurtec Odt$468$22,50816 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$107$2,18640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 neurology providers in Arkansas.

Other neurology in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →